Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.
Pharm Res
; 29(12): 3373-83, 2012 Dec.
Article
em En
| MEDLINE
| ID: mdl-22836184
ABSTRACT
PURPOSE:
The HDAC shuttling inhibitor, YK-4-272 functions by restricting nuclear shuttling of Class II HDACs. Pre-clinical investigations of YK-4-272 bioavailability, pharmacokinetics, in vivo toxicity and tumor growth inhibition were performed to determine its potential as an HDAC shuttling disruptor for use in clinical applications.METHODS:
The solubility, lipophilicity, in vitro metabolic stability, in vitro intestinal permeability, and in vivo pharmacokinetics of YK-4-272 were determined by HPLC methods. The anti-tumor activity of YK-4-272 was determined by monitoring athymic Balb/c nude mice bearing PC-3 xenografts.RESULTS:
Oral bioavailability of YK-4-272 is supported by its solubility (0.537 mg/mL) and apparent partition coefficient of 2.0. The compound was chemically and metabolically stable and not a substrate for CYP450. In Caco-2 cell transport studies, YK-4-272 was highly permeable. The time-concentration profile of YK-4-272 in plasma resulted in a C ( max ) of 2.47 µg/mL at 0.25 h with a AUC of 3.304 µg × h/mL. Treatment of PC-3 tumor xenografts with YK-4-272 showed significant growth delay.CONCLUSIONS:
YK-4-272 is stable and bio-available following oral administration. Growth inhibition of cancer cells and tumors was observed. These studies support advancing YK-4-272 for further evaluation as a novel HDAC shuttling inhibitor for use in cancer treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Histona Desacetilases
/
Histona Desacetilases
/
Neoplasias
/
Antineoplásicos
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pharm Res
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Estados Unidos